Cingulate (CING) Competitors $4.74 +0.02 (+0.32%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. SRZN, INCR, IMMX, ABOS, IMUX, GNTA, VNRX, ANEB, PYXS, and ADAPShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Surrozen (SRZN), InterCure (INCR), Immix Biopharma (IMMX), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Genenta Science (GNTA), VolitionRx (VNRX), Anebulo Pharmaceuticals (ANEB), Pyxis Oncology (PYXS), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors Surrozen InterCure Immix Biopharma Acumen Pharmaceuticals Immunic Genenta Science VolitionRx Anebulo Pharmaceuticals Pyxis Oncology Adaptimmune Therapeutics Cingulate (NASDAQ:CING) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment. Which has stronger earnings and valuation, CING or SRZN? Cingulate has higher earnings, but lower revenue than Surrozen. Cingulate is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$8.48-0.56Surrozen$11.64M6.14-$63.56M-$24.96-0.33 Is CING or SRZN more profitable? Cingulate's return on equity of -229.78% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -229.78% -142.28% Surrozen N/A -842.90%-71.32% Do analysts prefer CING or SRZN? Cingulate currently has a consensus target price of $26.00, indicating a potential upside of 449.10%. Surrozen has a consensus target price of $38.50, indicating a potential upside of 361.08%. Given Cingulate's higher possible upside, research analysts plainly believe Cingulate is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in CING or SRZN? 41.3% of Cingulate shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 45.2% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, CING or SRZN? Cingulate has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Does the media refer more to CING or SRZN? In the previous week, Cingulate and Cingulate both had 2 articles in the media. Surrozen's average media sentiment score of 1.87 beat Cingulate's score of 0.76 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummarySurrozen beats Cingulate on 7 of the 12 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.03M$2.92B$5.51B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.5620.5428.2719.87Price / SalesN/A258.87424.8998.56Price / CashN/A42.3835.5357.53Price / Book2.047.768.215.70Net Income-$15.55M-$55.11M$3.24B$257.71M7 Day Performance6.88%1.94%0.43%0.89%1 Month Performance6.40%12.55%7.84%11.09%1 Year Performance1,276.45%0.64%28.19%16.58% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.9356 of 5 stars$4.74+0.3%$26.00+449.1%+1,276.5%$20.03MN/A-0.5620SRZNSurrozen2.772 of 5 stars$8.35-0.1%$38.50+361.1%-11.6%$71.58M$10.65M-0.3380News CoverageGap DownINCRInterCure0.5531 of 5 stars$1.50-3.8%N/A-37.8%$71.09M$238.85M0.00350News CoveragePositive NewsHigh Trading VolumeIMMXImmix Biopharma3.5622 of 5 stars$2.62+2.7%$7.00+167.2%+43.9%$71.09MN/A-3.749ABOSAcumen Pharmaceuticals2.8481 of 5 stars$1.16flat$6.33+446.0%-56.2%$70.26MN/A-0.6020IMUXImmunic2.4891 of 5 stars$0.77+5.2%$11.60+1,416.3%-39.5%$69.68MN/A-0.6270GNTAGenenta Science2.6121 of 5 stars$3.98+4.7%$25.00+528.1%+3.4%$69.50MN/A0.007VNRXVolitionRx2.1095 of 5 stars$0.67-9.0%$3.50+419.8%+8.3%$69.38M$1.31M-1.8780News CoverageAnalyst ForecastGap UpANEBAnebulo Pharmaceuticals2.7364 of 5 stars$1.65-2.1%$5.50+234.3%-33.6%$69.02MN/A-6.334News CoverageGap UpHigh Trading VolumePYXSPyxis Oncology2.3814 of 5 stars$1.14+3.6%$9.00+689.5%-66.6%$68.14MN/A-0.7260ADAPAdaptimmune Therapeutics1.9626 of 5 stars$0.24-3.6%$1.35+460.6%-78.7%$66.26M$178.03M-0.89490 Related Companies and Tools Related Companies Surrozen Competitors InterCure Competitors Immix Biopharma Competitors Acumen Pharmaceuticals Competitors Immunic Competitors Genenta Science Competitors VolitionRx Competitors Anebulo Pharmaceuticals Competitors Pyxis Oncology Competitors Adaptimmune Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CING Stock Alerts